RNS Number : 1150J
Immupharma PLC
20 May 2025
 

 

 

 20 May 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Notice of AGM & Annual Report & Accounts

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting ("AGM") has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2024 has also been posted to shareholders today.

 

These documents will be available shortly, in electronic form, for download on the Company's website www.immupharma.co.uk.

 

ImmuPharma's AGM will be held on Thursday 12th June 2025 @ 11:00am (BST) at: The Malmaison Hotel, 18-21 Charterhouse Square, Barbican, London EC1M 6AH.

Ends

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman and Chief Executive Officer

+ 44 (0) 207 206 2650

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 203 368 3550

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 



 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAGPUWCAUPAUMR